Navigation Links
Danong Chen appointed CEO of Theranostics Health
Date:4/16/2008

ROCKVILLE, Md., April 16 /PRNewswire/ -- The Board of Managers of Theranostics Health, LLC, is pleased to announce that Dr. Danong Chen has been elected as the new President and CEO of Theranostics Health. Dr. Chen was previously the President and CEO of Tanox Inc., a publicly held biopharmaceutical company which was acquired by Genentech in 2007. Previously Dr. Chen was Vice-President of Strategy and Corporate Development at Tanox, responsible for guiding company strategy, evaluating new product opportunities and overseeing corporate development. Prior to her tenure at Tanox she served as a manager in the health care practice section at Arthur D. Little. Dr. Chen also holds a Ph.D. from Baylor College of Medicine in Houston, Texas as well as an MBA from Arthur D. Little School of Management in Boston, Massachusetts.

"I am very excited to join such a devoted, innovative and accomplished team and feel privileged to be given the opportunity by the Board to lead Theranostics Health, a company at the forefront of shaping a new paradigm of healthcare and disease management," Dr Chen noted. "We strongly believe that Danong's impressive scientific and business credentials combined with her proven management and leadership skills will enable Theranostics Health to achieve its true potential in the years ahead," said Dr. James Cooper, the Chairman of the Board.

About Theranostics Health

Theranostics Health is a privately held company founded in 2006. Its core technology is the breakthrough Reverse Phase Protein Microarray (RPMA) combined with Laser Capture Microdissection (LCM). The technology measures the activity of a large number of biomarkers, enabling pharmaceutical companies to accurately profile their drug candidates to facilitate efficient and effective drug development. More importantly, it enables physicians to tailor optimized therapies to their patients based on the biomarker profile of each individual patient, providing safer and more effective therapies. The technology, invented by the company's co-founders Drs. Emanuel Petricoin and Lance Liotta, was first published by them in 2001, has been featured in over 50 peer-reviewed publications and 20 scientific presentations within the past 2 years, and was successfully used in NCI-sponsored clinical trials. Currently, Theranostics Health is working with 5 of the top 10 global pharmaceutical companies in their drug R&D efforts. The company closed its seed financing of $5 million in 2007 and generated revenue in its first year of operations. For more information please email info@theranosticshealth.com or visit http://www.theranosticshealth.com.


'/>"/>
SOURCE Theranostics Health, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
2. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
3. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
4. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
5. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
6. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
7. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
8. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
9. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
10. David Mott Appointed Non Executive Director at Shire
11. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... that it has joined the Human Vaccines Project, a public-private partnership to ... cancer. , The Human Vaccines Project brings together leading pharmaceutical and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
Breaking Biology Technology:
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 ... innovative sensor-based diagnostic products, today announced the closing of a ... existing investors.  Proceeds from the financing will be used to ... hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has ...
Breaking Biology News(10 mins):